## **Core Concept**
The question tests knowledge of antiviral drugs, specifically those with dual activity against Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV). This requires understanding the spectrum of activity of various antiviral agents used in the treatment of these infections.

## **Why the Correct Answer is Right**
Tenofovir (Option ) is a nucleotide reverse transcriptase inhibitor (NtRTI) that exhibits dual antiviral activity against both HIV and HBV. It works by inhibiting the reverse transcriptase enzyme of HIV and the DNA polymerase of HBV, thereby suppressing the replication of both viruses. This dual activity makes tenofovir a valuable component in the treatment regimens for patients co-infected with HIV and HBV.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This option is incorrect because while it might be an antiviral, it does not have established dual activity against both HIV and HBV like tenofovir.
* **Option B:** - This option is incorrect as it does not represent a drug known for dual activity against HIV and HBV.
* **Option D:** - This option is incorrect because, similar to options A and B, it does not accurately represent a drug with established dual antiviral activity against HIV and HBV.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that tenofovir is often used in combination with other antiretroviral drugs for the treatment of HIV infection and can also be used for the treatment of chronic HBV infection. Its dual activity makes it particularly useful in managing patients with co-infections, highlighting the importance of selecting antiretroviral therapies that can address multiple viral infections simultaneously.

## **Correct Answer:** . Tenofovir